VSL#3® mentioned in ESPEN’s guidelines
These are the guidelines for “Clinical Nutrition in Inflammatory Bowel Disease” by ESPEN (European Society for Clinical Nutrition and Metabolism).
It is highlighted in the guidelines that there is considerable heterogeneity in the data regarding probiotics. However, VSL#3®, due to supporting scientific data, is specifically mentioned in the guidelines.
Probiotics therapy using E.coli Nissle 1917 or VSL#3® , but not necessarily other probiotics, can be considered for use in patients with mild to moderate UC, for the induction of remission, with a consensus of 92% (recommendation 14A).
Colectomized patients with pouch and pouchitis should be treated with probiotics such as VSL#3® if antibiotic treatment has failed. consensus 96%. (recommendation 33A).
VSL#3® is also recommended as primary treatment for pouchitis prevention in patients with UC who have undergone colectomy and pouch-anal anastomosis, 100% consensus. (recommendation 33B).